Use of autologous platelet-rich clots for the prevention of local injury bleeding in patients with severe inherited mucocutaneous bleeding disorders

Haemophilia

Volumn 17, Issue 4, 2011, Pages 620-624

  Nurden, P ^a   Youlouz Marfak, I ^a   Siberchicot, F ^b   Kostrzewa, E ^c   Andia, I ^d   Anitua, E ^d   Nurden, A T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

^b Service de Chirurgie Maxillofacial et de Stomatologie   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d Biotechnology Institute   (Spain)

Author keywords

Bleeding disorder; Glanzmann thrombasthenia autologous platelet rich plasma; Prevention of bleeding; Tissue healing; Von Willebrand's disease

Indexed keywords

TRANEXAMIC ACID;

ADULT; ARTICLE; BLEEDING; BLEEDING DISORDER; CASE REPORT; DENTAL SURGERY; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; GLANZMANN DISEASE; HEALING; HUMAN; MALE; PATIENT SAFETY; PRIORITY JOURNAL; SKIN BIOPSY; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; TISSUE REGENERATION; TOOTH EXTRACTION; VON WILLEBRAND DISEASE;

FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET-RICH PLASMA; POSTOPERATIVE HEMORRHAGE; THROMBASTHENIA; TRANSPLANTATION, AUTOLOGOUS; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2;

EID: 79959504827     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02480.x     Document Type: Article

References (24)

1. Bolton-Maggs PHB, Chalmers EA, Collins PW et al. A review of platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-33.
2. Nurden A, George JN. Inherited abnormalities of the platelet membrane: Glanzmann Thrombasthenia, Bernard-Soulier Syndrome, and other disorders. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ eds. Haemostasis and Thrombosis Basic Principles and Clinical Practice, 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, Chapter 66, 2006: 987-1010.
3. Nurden P, George JN, Nurden A. Inherited thrombocytopenias. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ eds. Haemostasis and Thrombosis Basic Principles and Clinical Practice, 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins. Chapter 65, 2006: 975-86.
4. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
5. Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 15: 113.
6. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-63.
7. Nurden P, Gobbi G, Nurden A et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from von Willebrand disease type 2B patients. Blood 2010; 115: 2649-56.
8. Roberts H, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
9. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci 2008; 13: 3532-48.
10. Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006; 24: 227-34.
11. Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome has type 2B von Willebrand disease with the VWF1316M mutation. Blood 2009; 113: 3348-51.
12. Nurden P, Lanza F, Bonnafous-Faurie C, Nurden A. A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene. Thromb Haemost 2007; 97: 319-21.
13. Anitua E, Andia I, Sanchez M et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res 2005; 23: 281-6.
14. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23: 177-89.
15. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 2007; 5: 2008-16.
16. Italiano JE, Richardson JL, Patel-Hett S et al. Angiogenesis is regulated by a novel mechanism: Pro- and anti-angiogenic proteins are organized into separate platelet α-granules and differentially released. Blood 2008; 111: 1227-33.
17. Smyth SS, McEver RP, Weyrich AS et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759-66.
18. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007; 177: 489-500.
19. Anitua I, Aguirre JJ, Algorta J et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomat Mater Res B Appl Biomater 2008; 84: 415-21.
20. Niewiarowski S, Levy-Toledano S, Caen JP. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res 1981; 23: 457-63.
21. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
22. Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91(Suppl. 6): ECR20.
23. Rakocz M, Lavie G, Martinowitz U. Glanzmann's thrombasthenia: the use of autologous fibrin glue in tooth extractions. ASDC J Dent Child 1995; 62: 129-31.
24. Anitua E, Sanchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 2010; 62: 741-52.